Literature DB >> 2054782

Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport.

L H Matherly1, C A Czajkowski, S M Angeles.   

Abstract

A K562 human erythroleukemia line (designated K562.4CF) was selected for increased tetrahydrofolate cofactor transport in a growth-limiting concentration (0.4 nM) of (6R,S)-5-formyltetrahydrofolate. K562.4CF cells exhibited elevated methotrexate uptake relative to parental cells, attributable to a 10-fold increased influx Vmax. The rate of methotrexate efflux in K562.4CF cells was somewhat increased (55%) as well. The transport system in K562.4CF cells had similar and high apparent binding affinities for methotrexate and 5-formyltetrahydrofolate and a markedly reduced affinity for folic acid, properties typically associated with the "classical" methotrexate/tetrahydrofolate cofactor transporter in tumor cells. Methotrexate uptake in K562.4CF cells decreased substantially under nonselective conditions; high levels of transport were restored in 0.4 nM 5-formyltetrahydrofolate. Treatment of parental and K562.4CF cells with N-hydroxysuccinimide methotrexate inhibited methotrexate influx. N-Hydroxysuccinimide-[3H]methotrexate (700 nM) radiolabeled a broadly migrating band at Mr 76,000-85,000. Incorporation from N-hydroxysuccinimide-[3H]methotrexate into this band was increased 7-fold in K562.4CF over parental cells and was blocked by unlabeled methotrexate, (6S)-5-formyltetrahydrofolate, or, to a lesser extent, folic acid. Whereas incubation with endoglycosidase F had no effect on the electrophoretic migration of the labeled protein, treatment with endoglycosidase F and glycopeptidase F, or endo-beta-galactosidase, reduced the apparent molecular weight to Mr approximately 52,000 or approximately 58,000, respectively. These results suggest that the high-affinity transporter in K562.4CF cells is an N-linked glycoprotein containing internal beta-galactosidic linkages in, or immediately after, unbranched poly-N-acetyllactosamine sequences. Differences in the level of glycosylation may, in part, account for the disparity in the apparent sizes of the homologous folate transport proteins from human and murine cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054782

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter.

Authors:  Johnathan R Whetstine; Robin M Flatley; Larry H Matherly
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

2.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

3.  Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter.

Authors:  Larry H Matherly; Zhanjun Hou
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

4.  Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.

Authors:  Ryan S Funk; Leon van Haandel; J Steven Leeder; Mara L Becker
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

5.  Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons.

Authors:  L Zhang; S C Wong; L H Matherly
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

6.  Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates.

Authors:  K N Chung; Y Saikawa; T H Paik; K H Dixon; T Mulligan; K H Cowan; P C Elwood
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Restoration of high-level transport activity by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: role of the transmembrane domain 6/7 linker region in reduced folate carrier function.

Authors:  Xiang Y Liu; Teah L Witt; Larry H Matherly
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

8.  Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking.

Authors:  Zhanjun Hou; Jianmei Wu; Jun Ye; Christina Cherian; Larry H Matherly
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

9.  Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2012-06-26       Impact factor: 4.436

Review 10.  Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.

Authors:  Zhanjun Hou; Larry H Matherly
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.